skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Zanolimumab (Code C91701)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Zanolimumab

Definition: A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities. Zanolimumab targets and binds to the CD4 receptor on certain T-cells thereby preventing the interaction between the CD4 receptor and the major histocompatibility complex class II molecule. This prevents activation of CD4 positive T cells. In addition, zanolimumab is able to induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD4-expressing tumor cells. CD4, a receptor located on a subset of T-lymphocytes, is upregulated in T-cell lymphomas.

Display Name: Zanolimumab

Label: Zanolimumab

NCI Thesaurus Code: C91701 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1957794  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-CD4 Monoclonal Antibody HuMax

External Source Codes: 
CAS Registry Number 652153-01-0 (see NLM ChemIDplus info)
FDA UNII Code HG3L8885M0
PDQ Closed Trial Search ID 352000
PDQ Open Trial Search ID 352000 (check for NCI PDQ open clinical trial info)
UMLS CUI C1957794

Other Properties:
     Name Value (qualifiers indented underneath)
code C91701
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom